2024年WCLC/ESMO肺癌围手术期免疫治疗进展解读  

Interpretation of perioperative immunotherapy for lung cancer in 2024 WCLC/ESMO

作　　者：李家贺 任小朋[1] 卢佳煜 张宸源 范锐涛 张旭旭 徐欣瑶 李桂珍 张继朋 李玮 卢强 LI Jiahe;REN Xiaopeng;LU Jiayu;ZHANG Chenyuan;FAN Ruitao;ZHANG Xuxu;XU Xinyao;LI Guizhen;ZHANG Jipeng;LI Wei;LU Qiang(Shaanxi University of Chinese Medicine,Xianyang,712046,Shaanxi,P.R.China;Department of Thoracic Surgery,Tangdu Hospital,Air Force Medical University,Xi'an,710038,P.R.China;Basic Medical College,Air Force Medical University,Xi'an,710032,P.R.China)

机构地区：[1]陕西中医药大学,陕西咸阳712046 [2]空军军医大学唐都医院胸腔外科,西安710038 [3]空军军医大学基础医学院,西安710032

出　　处：《中国胸心血管外科临床杂志》2025年第3期300-307,共8页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：陕西省重点研发计划项目(2024SF-GJHX-27);空军军医大学唐都医院2024学科助推计划研究项目(2024JSYX005);空军军医大学唐都医院新技术新业务(XJSXYW-2023011);空军军医大学唐都医院新技术新业务重点项目(XJSXYW-2021001)。

摘　　要：2024年世界肺癌大会(World Conference on Lung Cancer,WCLC)和欧洲肿瘤内科学会(European Society for Medical Oncology,ESMO)年会这两场肿瘤学盛会相继落下帷幕。作为肺癌及整个肿瘤领域最具权威性的年度盛会,WCLC和EMSO大会汇聚了全球顶尖的肿瘤学专家和科学家,共同分享、探讨和发表肿瘤领域的最新前沿进展。两次大会中,肺癌免疫治疗仍然是备受关注的热点话题。本文拟对两场大会报道的非小细胞肺癌围手术期免疫治疗重要研究进展进行总结和讨论。The 2024 World Conference on Lung Cancer(WCLC)and the European Society for Medical Oncology(ESMO)Annual Meeting,two of the most prestigious events in oncology,have concluded sequentially.As the most authoritative annual gatherings in lung cancer and the entire oncology field,the WCLC and ESMO conferences brought together top oncology experts and scientists from around the world to share,discuss,and publish the latest cutting-edge advancements in oncology.In both conferences,lung cancer immunotherapy remained a hot topic of considerable interest.This article aims to summarize and discuss the important research progress on perioperative immunotherapy for non-small cell lung cancer reported at the two conferences.

关 键 词：肺癌 世界肺癌大会 欧洲肿瘤内科学会 围手术期治疗 免疫 

分 类 号：R73[医药卫生—肿瘤]